A lymph node-targeted KRAS mutant peptide vaccine with a CpG oligo adjuvant (Amph-CpG-7909) in the AMPIFY-201 trial tested this therapy on 5 CRC patients, all from MMRp background. The gene discussed is KRAS; the disease is colorectal carcinoma.